Reuters logo
BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study
September 20, 2017 / 12:35 PM / a month ago

BRIEF-Alnylam's genetic disease drug meets main goal in phase 3 study

Sept 20 (Reuters) - Alnylam Pharmaceuticals Inc

* Sanofi and Alnylam report positive topline results from APOLLO phase 3 study of patisiran in Hereditary ATTR (HATTR) amyloidosis patients with polyneuropathy

* Alnylam Pharmaceuticals Inc - intends to file new drug application (NDA) in late 2017 and marketing authorisation application (MAA) in early 2018‍​

* Alnylam Pharmaceuticals - ‍​investigational RNAI therapeutic patisiran meets primary and all secondary endpoints

* Alnylam Pharmaceuticals Inc - “overall safety profile of patisiran was encouraging”‍​

* Alnylam Pharmaceuticals- all five other secondary endpoints demonstrated statistically significant favorable differences in patisiran arm versus placebo ‍​

* Alnylam Pharmaceuticals - in trial, at 18 months, mean change from baseline in MNIS+7 was significantly lower in patisiran group versus placebo‍​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below